FDA Approves Amgen and Allergan’s KanjintiAdjuvant Breast Cancer, Approvals, Biosimilars, Blockbusters, Companion Diagnostics, FDA, FDA/Regulatory, Metastatic Breast Cancer, Metastatic Gastric Cancer, Monoclonal AntibodiesAmgen Inc. and Allergan plc announced that the U.S. FDA approved Kanjinti (trastuzumab-anns) for all approved cancer indications of the reference product Herceptin. Read more June 13, 2019/by PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png PR Newswire2019-06-13 19:13:392019-06-14 13:19:53FDA Approves Amgen and Allergan’s Kanjinti